DaVita (DVA)
(Delayed Data from NYSE)
$149.96 USD
+1.08 (0.73%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $149.99 +0.03 (0.02%) 7:58 PM ET
2-Buy of 5 2
A Value B Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$149.96 USD
+1.08 (0.73%)
Updated Aug 15, 2024 04:00 PM ET
After-Market: $149.99 +0.03 (0.02%) 7:58 PM ET
2-Buy of 5 2
A Value B Growth B Momentum A VGM
Zacks News
Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.
Here's Why You Should Invest in DaVita (DVA) Stock For Now
by Zacks Equity Research
DaVita (DVA) continues to benefit from international expansion, strategic buyouts and strong demand of dialysis services.
Challenges for Monetary Policy: Global Week Ahead
by John Blank
Big-name retailers take center stage. Major department store earnings continue to disappoint. However, big-box retailers may tell us a different story about retail.
Is DaVita (DVA) a Profitable Stock for Value Investors Now?
by Zacks Equity Research
Let's see if DaVita (DVA) stock is a good choice for value-oriented investors right now from multiple angles.
5 Price-to-Book Value Picks to Improve Portfolio Returns
by Kinjel Shah
P/B ratio is emerging as a convenient tool for identifying low-priced stocks that have high growth prospects.
Outlook for Outpatient and Home Healthcare Industry Looks Bright
by Trina Mukherjee
Growth prospects look bright for the Zacks Outpatient and Home Healthcare industry, thanks to AI, cost effectiveness and rise in demand of drug rehabilitation centers.
The Zacks Analyst Blog Highlights: Alamos Gold, Chemed, Safehold, Franco-Nevada and DaVita
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Alamos Gold, Chemed, Safehold, Franco-Nevada and DaVita
DVA or CHE: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
DVA vs. CHE: Which Stock Is the Better Value Option?
5 Safe Picks Amid Yield Inversion and Geopolitical Concerns
by Nalak Das
Throughout this month, U.S. stock markets are witnessing extreme volatility. Equities are suffering as investors are flocking to safe-haven sovereign bonds.
Zacks.com featured highlights include: DaVita, Kraton, ADT, Universal Forest Products and International Game
by Zacks Equity Research
Zacks.com featured highlights include: DaVita, Kraton, ADT, Universal Forest Products and International Game
Why DaVita HealthCare (DVA) Might be Well Poised for a Surge
by Zacks Equity Research
DaVita HealthCare (DVA) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
A Time to Shift Gears: Zacks August Strategy
by John Blank
The latest Q2 GDP report showed us that the consumer is solid, but business fixed investment is lackluster.
The Zacks Analyst Blog Highlights: Industrial Logistics, Medpace, Unitil, DaVita and Telephone and Data
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Industrial Logistics, Medpace, Unitil, DaVita and Telephone and Data
5 Value Picks Boasting Strikingly Low EV/EBITDA Ratios
by Anindya Barman
We have screened value stocks based on EV/EBITDA ratio, which offers a clearer picture of a company's valuation and earnings potential.
Relative Price Strength Make These 5 Stocks Worth a Look Now
by Nilanjan Choudhury
Want to try an out-of-the-box approach to earn handsome returns? Tap these stocks with explosive relative price strength.
5 Stocks to Buy on a Possible Second Rate Cut in September
by Nalak Das
As signs of deterioration emerge, the central bank may feel compelled to cut rate for the second time in September.
Stock Market News For Aug 5, 2019
by Zacks Equity Research
Benchmarks closed in the red on Friday to post their worst single-day decline in a month.
Stock Market News for Aug 02, 2019
by Zacks Equity Research
Benchmarks closed lower on Thursday after President Trump announced plans to impose additional tariffs on imports from China.
DaVita (DVA) Earnings Beat, Revenues Miss Estimates in Q2
by Zacks Equity Research
DaVita (DVA) completes divestment of DMG unit to Optum for $4.34 billion.
DaVita HealthCare (DVA) Q2 Earnings Top Estimates
by Zacks Equity Research
DaVita HealthCare (DVA) delivered earnings and revenue surprises of 10.91% and -0.17%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
6 Promising Price-to-Book Value Stocks to Buy in August
by Kinjel Shah
P/B ratio is emerging as a convenient tool for identifying low-priced stocks that have high growth prospects.
Can BD Medical Drive Becton, Dickinson's (BDX) Q3 Earnings?
by Zacks Equity Research
Becton, Dickinson (BDX) expects to gain from core segmental strength in the third quarter.
Cigna (CI) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Cigna's (CI) Q2 earnings should reflect increase in revenues from growth across its segments and share buyback.
Is a Beat in the Cards for Humana's (HUM) Earnings in Q2?
by Zacks Equity Research
Humana's (HUM) second-quarter earnings are likely to gain traction from a solid revenue stream.
What's in the Cards for DaVita (DVA) This Earnings Season?
by Zacks Equity Research
DaVita (DVA) projects operating income within $460-$465 million for the second quarter.
Top Ranked Momentum Stocks to Buy for July 26th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, July 26th